Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360316 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL1360318 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL19532528 | 0.85 | CA1 (0.54) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL27302240 | 0.85 | CA1 (0.54) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL11402438 | 0.85 | CA1 (0.54) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL16445616 | 0.84 | RXRA (0.45) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL16445618 | 0.84 | RXRA (0.45) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL8839263 | 0.82 | SLC1A1 (0.73) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL13733029 | 0.82 | CA1 (0.51) | CA1CA2CA7CA9SLC1A1 | |
| SCHEMBL29097257 | 0.82 | CA1 (0.51) | CA1CA2CA7CA9SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AG (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4608453-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4583926-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4308551-B1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AG (DE) | 2025-04-09 | — | — | EP | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240368106-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| WO-2022194777-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-22 | — | — | WO | disclosed |
| EP-4059925-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2501683-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | Novartis AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| CN-101098855-B | 3- [2- (3-amido-2-oxo-2H-pyridin-1-yl) -acetylamino ] -4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | VERTEX PHARMA | 2012-06-06 | — | — | CN | disclosed |
| WO-2011061271-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| CN-101098855-A | 3- [2- (3-amido-2-oxo-2H-pyridin-1-yl) -acetylamino ] -4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | VERTEX PHARMA (US) | 2008-01-02 | — | — | CN | disclosed |
| US-7087622-B2 | Pyridone compounds as inhibitors of bacterial type III protein secreation systems | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| WO-2005110988-A1 | PYRIDONE COMPOUNDS AS INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256137-A1 | Pyridone compounds as inhibitors of bacterial type III protien secreation systems | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208987-A1 | EXATECAN-DERIVED ADC LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ADCY3, ADCY8, ADCY7 | CA1 1440/4885CA2 2396/4885CA7 419/4885 |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | CA1 4518/4885CA2 3730/4885CA7 3121/4885 |
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | MAG, GBA1, GLRX3 | CA1 106/4885CA2 303/4885CA7 71/4885 |
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | CA13, CCR1, GALC | CA1 17/4885CA2 37/4885CA7 10/4885 |
| US-20240368106-A1 | HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT | POLRMT, ACAT1, TFAM | CA1 4881/4885CA2 4741/4885CA7 4434/4885 |
| US-20050256137-A1 | Pyridone compounds as inhibitors of bacterial type III protien secreation systems | PROC, PSMB3, PANK3 | CA1 4649/4885CA2 4388/4885CA7 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.